Observational studyEmerging microbes & infections2019
Effects of cotrimoxazole prophylaxis on
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Emerging microbes & infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Current status and prospects in diagnosis of major opportunistic fungal infections among HIV-positive population in south provinces of China and neighboring countries that are suffering high prevalence of AIDS.Biosafety and health · 2026Review
- Advanced HIV disease: A review of diagnostic and prophylactic strategies.HIV medicine · 2023Review
- An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease.Journal of fungi (Basel, Switzerland) · 2023Review
- An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei.Clinical microbiology reviews · 2023Review
- Effect and Mechanism of Cotrimoxazole Against Talaromyces marneffei in vitro.Mycopathologia · 2022Article
- Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.BMC infectious diseases · 2022Article
- Clinical Characteristics, Laboratory Findings, and Prognosis in Patients WithFrontiers in medicine · 2022Article
- HIV-negative case ofThe Journal of international medical research · 2021Article
- Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 3 countries.
Junjun JiangGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.ORCID https://orcid.org/0000-0003-4905-9348
Fengxiang QinGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.ORCID https://orcid.org/0000-0003-1459-4826
Sirun MengFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Eric J NehlRollins School of Public Health, Emory University, Atlanta, GA, USA.
Jinping HuangFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Yanfen LiuFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Jun ZouFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Wenyi DongFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Jiegang HuangGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.
Hui ChenGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.
Ning ZangGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Bingyu LiangGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.
Chuanyi NingGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Yanyan LiaoGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Chaolian LuoGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Huifang LiuGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Xin LiuGuangxi Collaborative Innovation Center for Biomedicine, Life Sciences Institute, Guangxi Medical University, Nanning, People's Republic of China.
Jian WangGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.
Oulu ZhouGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.
Thuy LeDivision of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA.
Li YeGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.ORCID https://orcid.org/0000-0001-7688-4867
Fengyao WuFourth People's Hospital of Nanning, Nanning, People's Republic of China.
Hao LiangGuangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, School of Public Health, Guangxi Medical University, Nanning, People's Republic of China.ORCID https://orcid.org/0000-0001-7534-5124
Guangxi Medical University · CNThe Fourth People's Hospital · CNDuke University · USEmory University · US
Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MMaking an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV disease in Southeast AsiaR01AI143409 · NIAID · DUKE UNIVERSITY · PI LE, THUY · 2019 to 2024
$2.8MNIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI143409
Abstract
The dimorphic fungus
Indexed as
Acquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsChinaFemaleHIV InfectionsHumansMaleMiddle AgedMycosesProportional Hazards ModelsRetrospective StudiesSurvival AnalysisTalaromycesTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Retroviral AgentsTrimethoprim, Sulfamethoxazole Drug CombinationAIDSantiretroviral therapycotrimoxazoleHIVTalaromyces marneffei
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.